Technical superiority
NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.
Pipelines leadership
More than 10 First-in-Class R&D pipelines focusing on cancer vaccines , tumor immunomodulator, and virus vaccines
Team advantages
A top-notch complementarity team, bringing together top experts from tumor immunology, RNA delivery, molecular engineering, artificial intelligence, and industrialization fields
Resource integration
Gather strength by integrating top resources in research, industry, and clinical fields at home and abroad to break through obstacles
AI empowerment
AI empowers RNA throughout the entire flow process, accelerating research and development of drugs and technology upgrades
Development history
2021
December
RMB 500 million A+ round financing was completed
December
Strategic cooperation was reached with Integrated Nanotherapeutics
November
IIT trial for mRNA tumor neoantigen vaccine was initiated at Peking University Cancer Hospital
October
Strategic cooperation was reached with Innovent and MDimune
September
IIT trial for mRNA tumor neoantigen vaccine was initiated at Chinese PLA General Hospital (301 Hospital)
June
Beijing R&D center was put into use
2023
March
Strategic partnership was established with Gene+
February
IIT trial for the second mRNA tumor neoantigen vaccine was initiated at Chinese PLA General Hospital (301 Hospital)
2022
September
NeoCura (Beijing) was approved for municipal-level "Key Technology Innovation for Science and Technology-type Small and Micro Enterprises" policy support
July
IIT trial for mRNA tumor neoantigen vaccine was initiated at Peking Union Medical College Hospital in Beijing
January
Guangzhou GMP production center was put into use
January
R&D cooperation was reached with PhoreMost
2020
December
RMB 250 million A round financing was completed
August
NeoCura (Shenzhen) laboratory passed the NCCL quality evaluation with a full score
May
IIT trial for mRNA tumor neoantigen vaccine was initiated at the First Affiliated Hospital of Zhengzhou University
2020
2019
July
Shenzhen R&D center was officially put into use
2023
